JP6018361B2
(ja)
|
2008-01-31 |
2016-11-02 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
制御性t細胞活性を抑制するための、ヒトcd39に対する抗体およびその使用
|
TWI686405B
(zh)
|
2008-12-09 |
2020-03-01 |
建南德克公司 |
抗pd-l1抗體及其於增進t細胞功能之用途
|
WO2011159877A2
(en)
*
|
2010-06-18 |
2011-12-22 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
|
PL3409278T3
(pl)
|
2011-07-21 |
2021-02-22 |
Sumitomo Pharma Oncology, Inc. |
Heterocykliczne inhibitory kinazy białkowej
|
BR112014028826A8
(pt)
|
2012-05-15 |
2021-07-20 |
Bristol Myers Squibb Co |
anticorpos monoclonais, uso de anticorpos anti-pd1, anti-pd-l1 e anti-ctla-4 em imunoterapia e tratamento de câncer, bem como kits e processo de seleção de indivíduo para tratamento com anticorpo anti-pd-1
|
CN112587658A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
PL2904011T3
(pl)
|
2012-10-02 |
2018-01-31 |
Bristol Myers Squibb Co |
Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka
|
RU2015129551A
(ru)
*
|
2012-12-19 |
2017-01-25 |
Эмплиммьюн, Инк. |
Антитела к в7-н4 человека и их применение
|
KR20150100715A
(ko)
*
|
2012-12-21 |
2015-09-02 |
앰플리뮨, 인크. |
항-h7cr 항체
|
WO2014121085A1
(en)
|
2013-01-31 |
2014-08-07 |
Thomas Jefferson University |
Pd-l1 and pd-l2-based fusion proteins and uses thereof
|
CA2901269C
(en)
|
2013-03-06 |
2022-01-18 |
Astrazeneca Ab |
Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
|
WO2014151006A2
(en)
*
|
2013-03-15 |
2014-09-25 |
Genentech, Inc. |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
WO2014194293A1
(en)
*
|
2013-05-30 |
2014-12-04 |
Amplimmune, Inc. |
Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
|
WO2014209804A1
(en)
*
|
2013-06-24 |
2014-12-31 |
Biomed Valley Discoveries, Inc. |
Bispecific antibodies
|
PL3030262T3
(pl)
|
2013-08-08 |
2020-07-27 |
Cytune Pharma |
Złożona kompozycja farmaceutyczna
|
PL3444271T3
(pl)
|
2013-08-08 |
2022-03-07 |
Cytune Pharma |
Modulokiny oparte na il-15 i domenie sushi il-15ralfa
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
EP3043820A4
(en)
|
2013-09-13 |
2017-07-12 |
F. Hoffmann-La Roche AG |
Methods and compositions comprising purified recombinant polypeptides
|
RU2016107435A
(ru)
|
2013-09-13 |
2017-10-18 |
Дженентек, Инк. |
Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
|
HUE060420T2
(hu)
*
|
2013-09-13 |
2023-02-28 |
Beigene Switzerland Gmbh |
Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk
|
ES2728578T3
(es)
|
2013-09-20 |
2019-10-25 |
Bristol Myers Squibb Co |
Combinación de anticuerpos anti-LAG-3 y anticuerpos anti-PD-1 para tratar tumores
|
WO2015048312A1
(en)
*
|
2013-09-26 |
2015-04-02 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
SG11201604738TA
(en)
|
2013-12-12 |
2016-07-28 |
Shanghai Hengrui Pharm Co Ltd |
Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
|
EA201990240A1
(ru)
|
2013-12-24 |
2019-06-28 |
Бристол-Маерс Сквибб Компани |
Новые трициклические соединения в качестве противораковых средств
|
SG11201605455YA
(en)
|
2014-01-10 |
2016-08-30 |
Birdie Biopharmaceuticals Inc |
Compounds and compositions for treating egfr expressing tumors
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
WO2015134605A1
(en)
|
2014-03-05 |
2015-09-11 |
Bristol-Myers Squibb Company |
Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
NZ725006A
(en)
|
2014-03-12 |
2019-11-29 |
Yeda Res & Dev |
Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
|
US10519237B2
(en)
|
2014-03-12 |
2019-12-31 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
US9394365B1
(en)
|
2014-03-12 |
2016-07-19 |
Yeda Research And Development Co., Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
|
US10618963B2
(en)
|
2014-03-12 |
2020-04-14 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
PT3116909T
(pt)
|
2014-03-14 |
2020-01-30 |
Novartis Ag |
Moléculas de anticorpos para lag-3 e suas utilizações
|
KR20230144099A
(ko)
|
2014-05-15 |
2023-10-13 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료
|
CA2951259A1
(en)
|
2014-06-06 |
2015-12-10 |
Flexus Biosciences, Inc. |
Immunoregulatory agents
|
SG10201810507WA
(en)
|
2014-06-06 |
2018-12-28 |
Bristol Myers Squibb Co |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
EP3160505A4
(en)
|
2014-07-03 |
2018-01-24 |
BeiGene, Ltd. |
Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
|
AU2015286043B2
(en)
|
2014-07-09 |
2020-08-20 |
Birdie Biopharmaceuticals Inc. |
Anti-PD-L1 combinations for treating tumors
|
CN105440135A
(zh)
|
2014-09-01 |
2016-03-30 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
SG11201700207WA
(en)
|
2014-07-11 |
2017-02-27 |
Genentech Inc |
Anti-pd-l1 antibodies and diagnostic uses thereof
|
US10428146B2
(en)
|
2014-07-22 |
2019-10-01 |
Cb Therapeutics, Inc. |
Anti PD-1 antibodies
|
CN105330740B
(zh)
*
|
2014-07-30 |
2018-08-17 |
珠海市丽珠单抗生物技术有限公司 |
抗pd-1抗体及其应用
|
JP6909153B2
(ja)
|
2014-08-05 |
2021-07-28 |
アポロミクス インコーポレイテッド |
抗pd−l1抗体
|
US9982053B2
(en)
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
US9982052B2
(en)
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
WO2016022994A2
(en)
|
2014-08-08 |
2016-02-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
High affinity pd-1 agents and methods of use
|
WO2016040880A1
(en)
|
2014-09-13 |
2016-03-17 |
Novartis Ag |
Combination therapies of alk inhibitors
|
CN113929782A
(zh)
|
2014-09-16 |
2022-01-14 |
依奈特制药公司 |
对淋巴细胞中抑制途径的中和
|
SG11201701341UA
(en)
|
2014-10-10 |
2017-03-30 |
Innate Pharma |
Cd73 blockade
|
EP4029508A1
(en)
|
2014-10-10 |
2022-07-20 |
Idera Pharmaceuticals, Inc. |
Treatment of cancer using tlr9 agonists and checkpoint inhibitors
|
TN2017000129A1
(en)
|
2014-10-14 |
2018-10-19 |
Dana Farber Cancer Inst Inc |
Antibody molecules to pd-l1 and uses thereof
|
JP6821560B2
(ja)
|
2014-10-21 |
2021-01-27 |
サイクロン ファーマシューティカルズ インターナショナル エルティーディー.Sciclone Pharmaceuticals International Ltd. |
免疫刺激剤による癌治療
|
AU2015335921B2
(en)
|
2014-10-23 |
2020-06-25 |
Regeneron Pharmaceuticals, Inc. |
Novel CHO integration sites and uses thereof
|
JP6687612B2
(ja)
|
2014-10-24 |
2020-04-22 |
アストラゼネカ アクチボラグ |
組合せ
|
GB201419084D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-PD-1 antibodies
|
ES2851390T3
(es)
|
2014-10-29 |
2021-09-06 |
Five Prime Therapeutics Inc |
Terapia de combinación para el cáncer
|
UY36390A
(es)
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
|
AR102537A1
(es)
|
2014-11-05 |
2017-03-08 |
Flexus Biosciences Inc |
Agentes inmunomoduladores
|
WO2016073738A2
(en)
|
2014-11-05 |
2016-05-12 |
Flexus Biosciences, Inc. |
Immunoregulatory agents
|
EA038349B1
(ru)
|
2014-11-21 |
2021-08-12 |
Бристол-Маерс Сквибб Компани |
Антитела, содержащие модифицированные константные участки тяжелой цепи
|
EP3725808A1
(en)
|
2014-11-21 |
2020-10-21 |
Bristol-Myers Squibb Company |
Antibodies against cd73 and uses thereof
|
JP2017537927A
(ja)
|
2014-12-04 |
2017-12-21 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
がん(骨髄腫)を処置するための抗cs1および抗pd1抗体の併用
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
AR103232A1
(es)
|
2014-12-22 |
2017-04-26 |
Bristol Myers Squibb Co |
ANTAGONISTAS DE TGFbR
|
BR112017013385A2
(pt)
|
2014-12-23 |
2018-02-06 |
Bristol-Myers Squibb Company |
anticorpos para tigit
|
US10983128B2
(en)
|
2015-02-05 |
2021-04-20 |
Bristol-Myers Squibb Company |
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
|
ES2789331T3
(es)
|
2015-03-02 |
2020-10-26 |
Rigel Pharmaceuticals Inc |
Inhibidores de TGF-beta
|
BR112017018954A2
(pt)
|
2015-03-06 |
2018-05-15 |
Beyondspring Pharmaceuticals, Inc. |
uso de forma mutante de proteína ras e método para tratar câncer
|
JP6904570B2
(ja)
|
2015-03-06 |
2021-07-21 |
ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド |
脳腫瘍の治療方法
|
MA42971A
(fr)
|
2015-03-13 |
2018-08-15 |
Cytomx Therapeutics Inc |
Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
|
BR112017021021A2
(pt)
|
2015-04-03 |
2018-07-03 |
Bristol-Myers Squibb Company |
inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
|
TW201642897A
(zh)
|
2015-04-08 |
2016-12-16 |
F 星生物科技有限公司 |
Her2結合劑治療
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
MY188749A
(en)
|
2015-04-17 |
2021-12-28 |
Bristol Myers Squibb Co |
Compositions comprising a combination of nivolumab and ipilimumab
|
ES2861352T3
(es)
|
2015-04-28 |
2021-10-06 |
Bristol Myers Squibb Co |
Tratamiento del melanoma positivo para PD-L1 utilizando un anticuerpo anti-PD-1
|
US10174113B2
(en)
|
2015-04-28 |
2019-01-08 |
Bristol-Myers Squibb Company |
Treatment of PD-L1-negative melanoma using an anti-PD-1 antibody and an anti-CTLA-4 antibody
|
WO2016183114A1
(en)
|
2015-05-11 |
2016-11-17 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
EP3307740B1
(en)
|
2015-05-12 |
2019-12-18 |
Bristol-Myers Squibb Company |
5h-pyrido[3,2-b]indole compounds as anticancer agents
|
US9725449B2
(en)
|
2015-05-12 |
2017-08-08 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
US20180155429A1
(en)
|
2015-05-28 |
2018-06-07 |
Bristol-Myers Squibb Company |
Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
|
UY36687A
(es)
|
2015-05-29 |
2016-11-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Anticuerpos contra ox40 y sus usos
|
MA44594B1
(fr)
|
2015-05-29 |
2020-09-30 |
Memorial Sloan Kettering Cancer Center |
Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
|
WO2016196389A1
(en)
|
2015-05-29 |
2016-12-08 |
Bristol-Myers Squibb Company |
Treatment of renal cell carcinoma
|
KR20180011117A
(ko)
|
2015-05-31 |
2018-01-31 |
큐어제닉스 코포레이션 |
면역 요법용 복합 조성물
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
EP3307778A1
(en)
|
2015-06-12 |
2018-04-18 |
Bristol-Myers Squibb Company |
Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
|
TW201709929A
(zh)
|
2015-06-12 |
2017-03-16 |
宏觀基因股份有限公司 |
治療癌症的聯合療法
|
PE20181090A1
(es)
|
2015-06-24 |
2018-07-09 |
Janssen Biotech Inc |
Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38
|
JP2018526977A
(ja)
|
2015-06-29 |
2018-09-20 |
ザ ロックフェラー ユニヴァーシティ |
アゴニスト活性が増強されたcd40に対する抗体
|
EA201890285A1
(ru)
|
2015-07-13 |
2018-08-31 |
Сайтомкс Терапьютикс, Инк. |
Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
|
CN108026075B
(zh)
|
2015-07-13 |
2021-06-29 |
大连万春布林医药有限公司 |
普那布林组合物
|
LT3322731T
(lt)
|
2015-07-14 |
2021-03-25 |
Bristol-Myers Squibb Company |
Vėžio gydymo būdas, panaudojant imuninio kontrolinio taško inhibitorių; antikūnas, kuris prisiriša prie užprogramuotos mirties 1 receptoriaus (pd-1) arba prie užprogramuotos mirties ligando 1 (pd-l1)
|
US10399987B2
(en)
|
2015-07-28 |
2019-09-03 |
Bristol-Myer Squibb Company |
TGF beta receptor antagonists
|
EP3328419B1
(en)
|
2015-07-30 |
2021-08-25 |
MacroGenics, Inc. |
Pd-1-binding molecules and methods of use thereof
|
JP2018526989A
(ja)
|
2015-08-07 |
2018-09-20 |
ピエリス ファーマシューティカルズ ゲーエムベーハー |
Lag−3およびpd−1に特異的な新規融合ポリペプチド
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
CN106432494B9
(zh)
*
|
2015-08-11 |
2022-02-15 |
广州誉衡生物科技有限公司 |
新型抗-pd-1抗体
|
CA2993276A1
(en)
|
2015-08-11 |
2017-02-16 |
Yong Zheng |
Novel anti-pd-1 antibodies
|
AR105654A1
(es)
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
KR20180042370A
(ko)
|
2015-08-25 |
2018-04-25 |
브리스톨-마이어스 스큅 컴퍼니 |
Tgf 베타 수용체 길항제
|
CN107949573B
(zh)
|
2015-09-01 |
2022-05-03 |
艾吉纳斯公司 |
抗-pd-1抗体及其使用方法
|
MX2018003689A
(es)
|
2015-09-29 |
2018-04-30 |
Celgene Corp |
Proteinas de union a pd-1 y metodos para usarlas.
|
CN108368510B
(zh)
|
2015-09-30 |
2023-09-01 |
詹森生物科技公司 |
特异性结合人cd40的激动性抗体和使用方法
|
KR102146319B1
(ko)
*
|
2015-10-02 |
2020-08-25 |
에프. 호프만-라 로슈 아게 |
Pd1 및 tim3에 특이적인 이중특이성 항체
|
UA123826C2
(uk)
*
|
2015-10-02 |
2021-06-09 |
Ф. Хоффманн-Ля Рош Аг |
Антитіла до pd1 та способи їх застосування
|
MA45429A
(fr)
|
2015-10-08 |
2019-05-01 |
Macrogenics Inc |
Polythérapie pour le traitement du cancer
|
EP3362475B1
(en)
|
2015-10-12 |
2023-08-30 |
Innate Pharma |
Cd73 blocking agents
|
JP6954648B2
(ja)
|
2015-10-19 |
2021-10-27 |
シージー オンコロジー, インコーポレイテッド |
併用療法による固形腫瘍又はリンパ系腫瘍の治療方法
|
US10149887B2
(en)
|
2015-10-23 |
2018-12-11 |
Canbas Co., Ltd. |
Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
|
MX2018005517A
(es)
|
2015-11-02 |
2018-11-09 |
Five Prime Therapeutics Inc |
Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer.
|
MA43186B1
(fr)
|
2015-11-03 |
2022-03-31 |
Janssen Biotech Inc |
Anticorps se liant spécifiquement à pd-1 et leurs utilisations
|
EP3371311B1
(en)
|
2015-11-06 |
2021-07-21 |
Orionis Biosciences BV |
Bi-functional chimeric proteins and uses thereof
|
KR20180071376A
(ko)
*
|
2015-11-17 |
2018-06-27 |
쑤저우 선카디아 바이오파마수티컬즈 컴퍼니 리미티드 |
Pd-l1 항체, 이의 항원-결합 단편 및 이의 약제학적 용도
|
EP3377534A1
(en)
|
2015-11-18 |
2018-09-26 |
Bristol-Myers Squibb Company |
Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody
|
CN106699889A
(zh)
*
|
2015-11-18 |
2017-05-24 |
礼进生物医药科技(上海)有限公司 |
抗pd-1抗体及其治疗用途
|
US11213586B2
(en)
|
2015-11-19 |
2022-01-04 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)
|
AU2016359609B2
(en)
|
2015-11-23 |
2023-12-07 |
Five Prime Therapeutics, Inc. |
FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
|
FI3380522T3
(fi)
|
2015-11-25 |
2024-01-16 |
Visterra Inc |
Vasta-ainemolekyylejä april-proteiinille ja niiden käyttöjä
|
AU2016370376B2
(en)
|
2015-12-14 |
2023-12-14 |
Macrogenics, Inc. |
Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
|
EP3390406A1
(en)
|
2015-12-15 |
2018-10-24 |
Bristol-Myers Squibb Company |
Cxcr4 receptor antagonists
|
US10392442B2
(en)
|
2015-12-17 |
2019-08-27 |
Bristol-Myers Squibb Company |
Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
|
CN115252792A
(zh)
|
2016-01-07 |
2022-11-01 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-egfr组合
|
CN115554406A
(zh)
|
2016-01-07 |
2023-01-03 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-cd20组合
|
CN106943598A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技(北京)有限公司 |
用于治疗肿瘤的抗-her2组合
|
EP3403091B1
(en)
|
2016-01-11 |
2021-12-22 |
Technion Research & Development Foundation Limited |
Methods of determining prognosis of sepsis and treating same
|
KR20180101549A
(ko)
|
2016-01-21 |
2018-09-12 |
이나뜨 파르마 |
림프구에서의 저해 경로의 중화
|
US11214617B2
(en)
|
2016-01-22 |
2022-01-04 |
MabQuest SA |
Immunological reagents
|
CN109311981B
(zh)
|
2016-01-22 |
2022-08-23 |
马布奎斯特公司 |
Pd1特异性抗体
|
WO2017134305A1
(en)
|
2016-02-05 |
2017-08-10 |
Orionis Biosciences Nv |
Bispecific signaling agents and uses thereof
|
AU2017217426B2
(en)
|
2016-02-08 |
2022-12-01 |
Beyondspring Pharmaceuticals, Inc. |
Compositions containing tucaresol or its analogs
|
US11180546B2
(en)
|
2016-02-17 |
2021-11-23 |
Novartis Ag |
TGFbeta 2 antibodies
|
EA201891983A8
(ru)
|
2016-03-04 |
2020-05-28 |
Бристол-Майерс Сквибб Компани |
Комбинированная терапия антителами к cd73
|
WO2017153433A1
(en)
|
2016-03-08 |
2017-09-14 |
Innate Pharma |
Siglec neutralizing antibodies
|
WO2017156349A1
(en)
|
2016-03-10 |
2017-09-14 |
Cold Genesys, Inc. |
Methods of treating solid or lymphatic tumors by combination therapy
|
JP7137474B2
(ja)
|
2016-03-15 |
2022-09-14 |
メルサナ セラピューティクス,インコーポレイティド |
NaPi2b標的化抗体-薬物コンジュゲート及びその使用方法
|
WO2017165742A1
(en)
|
2016-03-24 |
2017-09-28 |
Millennium Pharmaceuticals, Inc. |
Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
|
JP7069032B2
(ja)
|
2016-03-24 |
2022-05-17 |
ミレニアム ファーマシューティカルズ, インコーポレイテッド |
がん免疫治療における胃腸の免疫関連有害事象の治療方法
|
EP3436829A1
(en)
|
2016-03-30 |
2019-02-06 |
Centre Léon-Bérard |
Lymphocytes expressing cd73 in cancerous patient dictates therapy
|
US11209441B2
(en)
|
2016-04-05 |
2021-12-28 |
Bristol-Myers Squibb Company |
Cytokine profiling analysis
|
BR112018071307A2
(pt)
|
2016-04-18 |
2019-02-26 |
Celldex Therapeutics, Inc. |
anticorpos agonistas que ligam cd40 humana e usos dos mesmos
|
US11066383B2
(en)
|
2016-05-04 |
2021-07-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
JP2019519485A
(ja)
|
2016-05-04 |
2019-07-11 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
インドールアミン2,3−ジオキシゲナーゼ阻害剤およびその使用方法
|
JP2019516682A
(ja)
|
2016-05-04 |
2019-06-20 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
インドールアミン2,3−ジオキシゲナーゼ阻害剤およびその使用方法
|
CN109415320A
(zh)
|
2016-05-04 |
2019-03-01 |
百时美施贵宝公司 |
吲哚胺2,3-双加氧酶的抑制剂及其使用方法
|
US10696648B2
(en)
|
2016-05-04 |
2020-06-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
AR108377A1
(es)
*
|
2016-05-06 |
2018-08-15 |
Medimmune Llc |
Proteínas de unión biespecíficas y sus usos
|
WO2017194782A2
(en)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Therapeutic targeting of non-cellular structures
|
TWI822521B
(zh)
|
2016-05-13 |
2023-11-11 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
WO2017194783A1
(en)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Targeted mutant interferon-beta and uses thereof
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
CN105968200B
(zh)
*
|
2016-05-20 |
2019-03-15 |
瑞阳(苏州)生物科技有限公司 |
抗人pd-l1人源化单克隆抗体及其应用
|
CN106008714B
(zh)
|
2016-05-24 |
2019-03-15 |
瑞阳(苏州)生物科技有限公司 |
抗人pd-1人源化单克隆抗体及其应用
|
KR20230091191A
(ko)
|
2016-05-27 |
2023-06-22 |
아게누스 인코포레이티드 |
항-tim-3 항체 및 이의 사용 방법
|
WO2017210335A1
(en)
|
2016-06-01 |
2017-12-07 |
Bristol-Myers Squibb Company |
Imaging methods using 18f-radiolabeled biologics
|
KR20190008962A
(ko)
|
2016-06-02 |
2019-01-25 |
브리스톨-마이어스 스큅 컴퍼니 |
림프종 치료에서의 항-cd30 항체와 조합된 항-pd-1 항체의 용도
|
US11083790B2
(en)
|
2016-06-02 |
2021-08-10 |
Bristol-Myers Squibb Company |
Treatment of Hodgkin lymphoma using an anti-PD-1 antibody
|
KR20190015408A
(ko)
|
2016-06-03 |
2019-02-13 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법에 사용하기 위한 항-pd-1 항체
|
JP2019517498A
(ja)
|
2016-06-03 |
2019-06-24 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
再発性小細胞肺癌の処置方法において使用するための抗pd−1抗体
|
KR102515509B1
(ko)
|
2016-06-03 |
2023-03-28 |
브리스톨-마이어스 스큅 컴퍼니 |
결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
|
RU2760348C2
(ru)
|
2016-06-06 |
2021-11-24 |
Бейондспринг Фармасьютикалс, Инк. |
Способ уменьшения нейтропении
|
CA3029813A1
(en)
|
2016-06-13 |
2017-12-21 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
WO2018029474A2
(en)
|
2016-08-09 |
2018-02-15 |
Kymab Limited |
Anti-icos antibodies
|
MX2018016364A
(es)
|
2016-06-20 |
2019-11-28 |
Kymab Ltd |
Anticuerpos anti-pd-l1.
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
RU2021127872A
(ru)
|
2016-06-30 |
2021-11-09 |
Онкорус, Инк. |
Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов
|
JP6993056B2
(ja)
|
2016-07-05 |
2022-02-15 |
ベイジーン リミテッド |
癌治療のためのpd-1アンタゴニスト及びraf阻害剤の組合せ
|
CA3029902A1
(en)
|
2016-07-07 |
2018-01-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Antibody adjuvant conjugates
|
JP7027401B2
(ja)
|
2016-07-14 |
2022-03-01 |
ブリストル-マイヤーズ スクイブ カンパニー |
Tim3に対する抗体およびその使用
|
WO2018017633A1
(en)
|
2016-07-21 |
2018-01-25 |
Bristol-Myers Squibb Company |
TGF Beta RECEPTOR ANTAGONISTS
|
US11858996B2
(en)
|
2016-08-09 |
2024-01-02 |
Kymab Limited |
Anti-ICOS antibodies
|
AU2017313085A1
(en)
|
2016-08-19 |
2019-03-14 |
Beigene Switzerland Gmbh |
Use of a combination comprising a Btk inhibitor for treating cancers
|
CN106977602B
(zh)
*
|
2016-08-23 |
2018-09-25 |
中山康方生物医药有限公司 |
一种抗pd1单克隆抗体、其药物组合物及其用途
|
CN106967172B
(zh)
|
2016-08-23 |
2019-01-08 |
康方药业有限公司 |
抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
|
WO2018035710A1
(en)
|
2016-08-23 |
2018-03-01 |
Akeso Biopharma, Inc. |
Anti-ctla4 antibodies
|
EP3503916A1
(en)
|
2016-08-26 |
2019-07-03 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
WO2018048975A1
(en)
|
2016-09-09 |
2018-03-15 |
Bristol-Myers Squibb Company |
Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
|
US10766958B2
(en)
|
2016-09-19 |
2020-09-08 |
Celgene Corporation |
Methods of treating vitiligo using PD-1 binding antibodies
|
JP2019531284A
(ja)
|
2016-09-19 |
2019-10-31 |
セルジーン コーポレイション |
Pd−1結合タンパク質を使用して免疫障害を治療する方法
|
US11390675B2
(en)
|
2016-09-21 |
2022-07-19 |
Nextcure, Inc. |
Antibodies for Siglec-15 and methods of use thereof
|
EA201990285A1
(ru)
|
2016-09-29 |
2019-12-30 |
Бейджин Ханми Фармасьютикал Ко., Лтд. |
Гетеродимерные иммуноглобулиновые конструкции и способы их получения
|
WO2018071500A1
(en)
|
2016-10-11 |
2018-04-19 |
Agenus Inc. |
Anti-lag-3 antibodies and methods of use thereof
|
ES2917000T3
(es)
|
2016-10-24 |
2022-07-06 |
Orionis Biosciences BV |
Interferón-gamma mutante diana y usos del mismo
|
US20190315865A1
(en)
|
2016-10-28 |
2019-10-17 |
Bristol-Myers Squibb Company |
Methods of treating urothelial carcinoma using an anti-pd-1 antibody
|
UY37463A
(es)
|
2016-11-02 |
2018-05-31 |
Glaxosmithkline Ip No 2 Ltd |
Proteínas de unión
|
BR112019008223A2
(pt)
|
2016-11-03 |
2019-07-16 |
Bristol-Myers Squibb Company |
anticorpos anti-ctla-4 ativáveis e usos dos mesmos
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
US10660909B2
(en)
|
2016-11-17 |
2020-05-26 |
Syntrix Biosystems Inc. |
Method for treating cancer using chemokine antagonists
|
MX2019005858A
(es)
|
2016-11-18 |
2019-08-12 |
Beijing Hanmi Pharmaceutical Co Ltd |
Anticuerpo biespecifico heterodimerico estructural de anticuerpo natural anti-pd-1/anti-her2 y metodo para preparar el mismo.
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
TW201825119A
(zh)
|
2016-11-30 |
2018-07-16 |
日商協和醱酵麒麟有限公司 |
使用抗ccr4抗體及抗pd-1抗體治療癌症之方法
|
BR112019011651A2
(pt)
|
2016-12-07 |
2020-01-07 |
Agenus Inc. |
Anticorpos anti-cttla-4 e métodos de uso dos mesmos
|
CN110300599A
(zh)
|
2016-12-07 |
2019-10-01 |
艾吉纳斯公司 |
抗体和其使用方法
|
WO2018112360A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating cancer
|
WO2018112364A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating melanoma
|
RU2766582C2
(ru)
|
2016-12-23 |
2022-03-15 |
Ремд Биотерапьютикс, Инк. |
Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
|
CN113480530A
(zh)
|
2016-12-26 |
2021-10-08 |
阿里根公司 |
芳香烃受体调节剂
|
US10961239B2
(en)
|
2017-01-05 |
2021-03-30 |
Bristol-Myers Squibb Company |
TGF beta receptor antagonists
|
WO2018127570A1
(en)
|
2017-01-05 |
2018-07-12 |
Netris Pharma |
Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs
|
WO2018129381A1
(en)
|
2017-01-06 |
2018-07-12 |
Beyondspring Pharmaceuticals, Inc. |
Tubulin binding compounds and therapeutic use thereof
|
BR112019014510A2
(pt)
|
2017-01-13 |
2020-02-18 |
Agenus Inc. |
Receptores de célula t que se ligam ao ny-eso-1 e métodos de uso dos mesmos
|
AU2018211064A1
(en)
*
|
2017-01-18 |
2019-09-05 |
Genentech, Inc. |
Idiotypic antibodies against anti-PD-L1 antibodies and uses thereof
|
WO2018134279A1
(en)
|
2017-01-18 |
2018-07-26 |
Pieris Pharmaceuticals Gmbh |
Novel fusion polypeptides specific for lag-3 and pd-1
|
EA201991729A1
(ru)
|
2017-01-20 |
2019-12-30 |
Санофи |
Антитела к tgf-бета и их применение
|
EP4310082A3
(en)
|
2017-01-20 |
2024-04-10 |
Arcus Biosciences, Inc. |
Azolopyrimidine for the treatment of cancer-related disorders
|
TW202313678A
(zh)
|
2017-01-20 |
2023-04-01 |
法商賽諾菲公司 |
抗TGF-β抗體及其用途
|
US20200237874A1
(en)
|
2017-01-20 |
2020-07-30 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
AR110755A1
(es)
|
2017-01-20 |
2019-05-02 |
Genzyme Corp |
Anticuerpos dirigidos a hueso
|
EP3573989A4
(en)
|
2017-01-25 |
2020-11-18 |
Beigene, Ltd. |
CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) -PIPERIDINE-4-YL) -2- (4-PHENOXYPHENYL) -4,5,6,7-TETRAHYDROPYRAZOLO [1,5-A ] PYRIMIDINE-3-CARBOXAMIDE, MANUFACTURING AND USES THEREOF
|
IL268305B1
(en)
|
2017-02-01 |
2024-04-01 |
Beyondspring Pharmaceuticals Inc |
Palinabolin in combination with one or more G-CSF drugs for use in the drug treatment of docetaxel-induced neutropenia
|
US10906985B2
(en)
|
2017-02-06 |
2021-02-02 |
Orionis Biosciences, Inc. |
Targeted engineered interferon and uses thereof
|
US20200023071A1
(en)
|
2017-02-06 |
2020-01-23 |
Innate Pharma |
Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
|
KR102642385B1
(ko)
|
2017-02-06 |
2024-03-04 |
오리오니스 바이오사이언시스 엔브이 |
표적화된 키메라 단백질 및 이의 용도
|
KR20190115053A
(ko)
|
2017-02-10 |
2019-10-10 |
노파르티스 아게 |
1-(4-아미노-5-브로모-6-(1h-피라졸-1-일)피리미딘-2-일)-1h-피라졸-4-올 및 암 치료에 있어서의 이의 용도
|
TWI674261B
(zh)
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
EP3585431A4
(en)
|
2017-02-24 |
2020-12-16 |
MacroGenics, Inc. |
BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING TO CD137 AND TUMOR ANTIGENS, AND THEIR USES
|
UY37621A
(es)
|
2017-02-28 |
2018-09-28 |
Sanofi Sa |
Arn terapéutico que codifica citoquinas
|
WO2018160538A1
(en)
|
2017-02-28 |
2018-09-07 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
US11578136B2
(en)
|
2017-03-16 |
2023-02-14 |
Innate Pharma |
Compositions and methods for treating cancer
|
KR20190133213A
(ko)
|
2017-03-31 |
2019-12-02 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
US20200031944A1
(en)
|
2017-03-31 |
2020-01-30 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer using anti-gitr antibodies
|
SG11201909156RA
(en)
|
2017-04-01 |
2019-10-30 |
Beijing hanmi pharm co ltd |
Anti-pd-l1/anti-pd-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof
|
PE20191494A1
(es)
|
2017-04-03 |
2019-10-21 |
Hoffmann La Roche |
Inmunoconjugados de un anticuerpo anti-pd-1 con un il-2 mutante o con il-15
|
CN116375876A
(zh)
|
2017-04-05 |
2023-07-04 |
豪夫迈·罗氏有限公司 |
特异性结合pd1和lag3的双特异性抗体
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
BR112019017241A2
(pt)
|
2017-04-13 |
2020-04-14 |
Agenus Inc |
anticorpos anti-cd137 e métodos de uso dos mesmos
|
CN108728444A
(zh)
|
2017-04-18 |
2018-11-02 |
长春华普生物技术股份有限公司 |
免疫调节性多核苷酸及其应用
|
EP3612234B1
(en)
|
2017-04-20 |
2024-03-13 |
ADC Therapeutics SA |
Combination therapy with an anti-axl antibody-drug conjugate
|
CN106939049B
(zh)
*
|
2017-04-20 |
2019-10-01 |
苏州思坦维生物技术股份有限公司 |
拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用
|
MX2019012465A
(es)
|
2017-04-20 |
2020-07-27 |
Adc Therapeutics Sa |
Terapia combinada con un conjugado de anticuerpo y farmaco anti-cd25.
|
SG11201909710XA
(en)
|
2017-04-21 |
2019-11-28 |
Kyn Therapeutics |
Indole ahr inhibitors and uses thereof
|
WO2018200430A1
(en)
|
2017-04-26 |
2018-11-01 |
Bristol-Myers Squibb Company |
Methods of antibody production that minimize disulfide bond reduction
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
US11021537B2
(en)
|
2017-05-01 |
2021-06-01 |
Agenus Inc. |
Anti-TIGIT antibodies and methods of use thereof
|
US11066392B2
(en)
|
2017-05-12 |
2021-07-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
CN110891974B
(zh)
|
2017-05-12 |
2021-08-06 |
哈普恩治疗公司 |
间皮素结合蛋白质
|
US11685787B2
(en)
|
2017-05-16 |
2023-06-27 |
Bristol-Myers Squibb Company |
Treatment of cancer with anti-GITR agonist antibodies
|
CN110636846B
(zh)
|
2017-05-17 |
2023-05-16 |
艾库斯生物科学有限公司 |
用于治疗癌症相关疾病的喹唑啉吡唑衍生物
|
AR111760A1
(es)
|
2017-05-19 |
2019-08-14 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
|
CN110719915A
(zh)
|
2017-05-25 |
2020-01-21 |
百时美施贵宝公司 |
包含经修饰的重链恒定区的抗体
|
CN110691795A
(zh)
|
2017-05-30 |
2020-01-14 |
百时美施贵宝公司 |
包含抗-lag3抗体、pd-1途径抑制剂和免疫治疗剂组合的组合物
|
CA3060984A1
(en)
|
2017-05-30 |
2018-12-06 |
Bristol-Myers Squibb Company |
Treatment of lag-3 positive tumors
|
EP3630179A2
(en)
|
2017-05-30 |
2020-04-08 |
Bristol-Myers Squibb Company |
Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
|
JOP20190279A1
(ar)
|
2017-05-31 |
2019-11-28 |
Novartis Ag |
الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة
|
JP2020522508A
(ja)
|
2017-06-01 |
2020-07-30 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
抗pd−1抗体を用いる腫瘍の治療方法
|
US11168144B2
(en)
|
2017-06-01 |
2021-11-09 |
Cytomx Therapeutics, Inc. |
Activatable anti-PDL1 antibodies, and methods of use thereof
|
CN110997725A
(zh)
*
|
2017-06-12 |
2020-04-10 |
蓝鳍生物医药公司 |
抗-il1rap抗体和抗体药物缀合物
|
US11318211B2
(en)
|
2017-06-14 |
2022-05-03 |
Adc Therapeutics Sa |
Dosage regimes for the administration of an anti-CD19 ADC
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
JP2020524694A
(ja)
|
2017-06-22 |
2020-08-20 |
ノバルティス アーゲー |
がんの処置における使用のためのIL−1β結合性抗体
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
|
EP3641812A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
|
US11517567B2
(en)
|
2017-06-23 |
2022-12-06 |
Birdie Biopharmaceuticals, Inc. |
Pharmaceutical compositions
|
US11597768B2
(en)
|
2017-06-26 |
2023-03-07 |
Beigene, Ltd. |
Immunotherapy for hepatocellular carcinoma
|
WO2019003164A1
(en)
|
2017-06-27 |
2019-01-03 |
Neuracle Science Co., Ltd. |
USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF CANCERS
|
CA3066747A1
(en)
|
2017-06-27 |
2019-01-03 |
Novartis Ag |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
EP3421494A1
(en)
|
2017-06-29 |
2019-01-02 |
Sanofi |
Use of isatuximab in combination with an anti-pd-1 antibody
|
JP2020526520A
(ja)
|
2017-06-30 |
2020-08-31 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Ido阻害剤の非晶質形体および結晶形体
|
TW201920275A
(zh)
|
2017-07-06 |
2019-06-01 |
荷蘭商米樂斯股份有限公司 |
藉由細胞表現之調控生物活性的抗體
|
AU2018298676A1
(en)
|
2017-07-10 |
2019-12-19 |
Innate Pharma |
Siglec-9-neutralizing antibodies
|
EP3652166A1
(en)
|
2017-07-14 |
2020-05-20 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
US20200172617A1
(en)
|
2017-07-20 |
2020-06-04 |
Novartis Ag |
Dosage regimens of anti-lag-3 antibodies and uses thereof
|
JP2020527158A
(ja)
|
2017-07-21 |
2020-09-03 |
ノビミューン エスアー |
多重特異性抗体混合物の生成およびその使用方法
|
JP7274454B2
(ja)
|
2017-07-28 |
2023-05-16 |
ブリストル-マイヤーズ スクイブ カンパニー |
チェックポイント阻害薬のための予測末梢血バイオマーカー
|
KR20200032180A
(ko)
|
2017-07-28 |
2020-03-25 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
MX2020001451A
(es)
|
2017-08-07 |
2020-08-06 |
Amgen Inc |
Tratamiento de cancer de mama triple negativo o cancer colorrectal con metastasis hepaticas con un anticuerpo anti-pd-l1 y un virus oncolitico.
|
JP7269917B2
(ja)
|
2017-08-17 |
2023-05-09 |
イケナ オンコロジー, インコーポレイテッド |
Ahr阻害剤およびその使用
|
SG11202000387YA
(en)
|
2017-08-25 |
2020-03-30 |
Five Prime Therapeutics Inc |
B7-h4 antibodies and methods of use thereof
|
US11787859B2
(en)
|
2017-08-28 |
2023-10-17 |
Bristol-Myers Squibb Company |
TIM-3 antagonists for the treatment and diagnosis of cancers
|
CN111032672A
(zh)
|
2017-08-31 |
2020-04-17 |
百时美施贵宝公司 |
作为抗癌剂的环二核苷酸
|
KR102651946B1
(ko)
|
2017-08-31 |
2024-03-26 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
JP7208225B2
(ja)
|
2017-08-31 |
2023-01-18 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗癌剤としての環状ジヌクレオチド
|
JP7387585B2
(ja)
|
2017-09-04 |
2023-11-28 |
アジェナス インコーポレイテッド |
混合系統白血病(mll)特異的ホスホペプチドに結合するt細胞受容体およびその使用方法
|
US11021540B2
(en)
|
2017-09-07 |
2021-06-01 |
Augusta University Research Institute, Inc. |
Antibodies to programmed cell death protein 1
|
JP7196160B2
(ja)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー, インコーポレイテッド |
Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン
|
US11623932B2
(en)
|
2017-09-22 |
2023-04-11 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
CA3074588A1
(en)
|
2017-10-06 |
2019-04-11 |
Innate Pharma |
Restoration of t cell activity via the cd39/cd73 axis
|
US11649212B2
(en)
|
2017-10-09 |
2023-05-16 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
WO2019074824A1
(en)
|
2017-10-09 |
2019-04-18 |
Bristol-Myers Squibb Company |
INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
|
CN111344297B
(zh)
|
2017-10-10 |
2023-10-20 |
百时美施贵宝公司 |
作为抗癌剂的环二核苷酸
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
JP2020536894A
(ja)
|
2017-10-15 |
2020-12-17 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
腫瘍処置法
|
KR20200065065A
(ko)
|
2017-10-16 |
2020-06-08 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
WO2019082020A1
(en)
|
2017-10-27 |
2019-05-02 |
Pfizer Inc. |
ANTIBODIES AND CONJUGATES CD123-SPECIFIC ANTIBODIES AND USES THEREOF
|
EP3704159A1
(en)
|
2017-11-01 |
2020-09-09 |
Bristol-Myers Squibb Company |
Immunostimulatory agonistic antibodies for use in treating cancer
|
SG11202003237QA
(en)
*
|
2017-11-02 |
2020-05-28 |
Systimmune Inc |
Bispecific antibodies and methods of making and using thereof
|
JP7167146B2
(ja)
|
2017-11-06 |
2022-11-08 |
ブリストル-マイヤーズ スクイブ カンパニー |
Hpk1阻害剤として有用なイソフラノン化合物
|
CN111213059B
(zh)
|
2017-11-06 |
2024-01-09 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
CN111315397A
(zh)
|
2017-11-06 |
2020-06-19 |
百时美施贵宝公司 |
治疗肿瘤的方法
|
CN111655288A
(zh)
|
2017-11-16 |
2020-09-11 |
诺华股份有限公司 |
组合疗法
|
TW201925194A
(zh)
|
2017-11-20 |
2019-07-01 |
美商雅里俊公司 |
吲哚化合物及其用途
|
WO2019104289A1
(en)
|
2017-11-27 |
2019-05-31 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
CN111801334B
(zh)
|
2017-11-29 |
2023-06-09 |
百济神州瑞士有限责任公司 |
使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
|
KR20200096253A
(ko)
|
2017-11-30 |
2020-08-11 |
노파르티스 아게 |
Bcma-표적화 키메라 항원 수용체, 및 이의 용도
|
WO2019122882A1
(en)
|
2017-12-19 |
2019-06-27 |
Kymab Limited |
Bispecific antibody for icos and pd-l1
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
US20220305127A1
(en)
|
2017-12-21 |
2022-09-29 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
WO2019133531A1
(en)
|
2017-12-26 |
2019-07-04 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
CN109970857B
(zh)
*
|
2017-12-27 |
2022-09-30 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
CN111788227A
(zh)
|
2017-12-27 |
2020-10-16 |
百时美施贵宝公司 |
抗cd40抗体及其用途
|
JP2021508477A
(ja)
|
2017-12-29 |
2021-03-11 |
オンコラス, インコーポレイテッド |
治療用ポリペプチドの腫瘍溶解性ウイルス送達
|
US11324774B2
(en)
|
2018-01-05 |
2022-05-10 |
Augusta University Research Institute, Inc. |
Compositions of oral alkaline salts and metabolic acid inducers and uses thereof
|
WO2019136112A1
(en)
|
2018-01-05 |
2019-07-11 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
WO2019136432A1
(en)
|
2018-01-08 |
2019-07-11 |
Novartis Ag |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
CN111770936A
(zh)
|
2018-01-12 |
2020-10-13 |
百时美施贵宝公司 |
抗il-8抗体和抗pd-1抗体联合治疗用于治疗癌症
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
US20220089720A1
(en)
|
2018-01-12 |
2022-03-24 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
EP3740506A1
(en)
|
2018-01-16 |
2020-11-25 |
Bristol-Myers Squibb Company |
Methods of treating cancer with antibodies against tim3
|
CA3096287A1
(en)
|
2018-01-22 |
2019-07-25 |
Pascal Biosciences Inc. |
Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
|
SG11202006823XA
(en)
|
2018-01-22 |
2020-08-28 |
Bristol Myers Squibb Co |
Compositions and methods of treating cancer
|
KR20200112881A
(ko)
|
2018-01-24 |
2020-10-05 |
비욘드스프링 파마수티컬스, 인코포레이티드. |
플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
|
SG11202006832YA
(en)
|
2018-01-29 |
2020-08-28 |
Merck Patent Gmbh |
Gcn2 inhibitors and uses thereof
|
TWI816742B
(zh)
|
2018-01-29 |
2023-10-01 |
美商維泰克斯製藥公司 |
Gcn2抑制劑及其用途
|
CA3090249A1
(en)
|
2018-01-31 |
2019-08-08 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
WO2019149716A1
(en)
|
2018-01-31 |
2019-08-08 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
AU2019215440A1
(en)
|
2018-02-05 |
2020-08-27 |
Orionis Biosciences, Inc. |
Fibroblast binding agents and use thereof
|
US20200405806A1
(en)
|
2018-02-08 |
2020-12-31 |
Bristol-Myers Squibb Company |
Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors
|
WO2019153200A1
(zh)
|
2018-02-08 |
2019-08-15 |
北京韩美药品有限公司 |
抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
|
EP3752203A1
(en)
|
2018-02-13 |
2020-12-23 |
Novartis AG |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
US10519187B2
(en)
|
2018-02-13 |
2019-12-31 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
WO2019165315A1
(en)
|
2018-02-23 |
2019-08-29 |
Syntrix Biosystems Inc. |
Method for treating cancer using chemokine antagonists alone or in combination
|
US20210002373A1
(en)
|
2018-03-01 |
2021-01-07 |
Nextcure, Inc. |
KLRG1 Binding Compositions and Methods of Use Thereof
|
CN111971308A
(zh)
|
2018-03-02 |
2020-11-20 |
戊瑞治疗有限公司 |
B7-h4抗体及其使用方法
|
JP7250808B2
(ja)
|
2018-03-08 |
2023-04-03 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗がん剤としての環状ジヌクレオチド
|
BR112020019083A2
(pt)
|
2018-03-21 |
2020-12-29 |
Five Prime Therapeutics, Inc. |
Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
|
CN111886256A
(zh)
|
2018-03-23 |
2020-11-03 |
百时美施贵宝公司 |
抗mica和/或micb抗体及其用途
|
CN111971306A
(zh)
|
2018-03-30 |
2020-11-20 |
百时美施贵宝公司 |
治疗肿瘤的方法
|
WO2019195452A1
(en)
|
2018-04-04 |
2019-10-10 |
Bristol-Myers Squibb Company |
Anti-cd27 antibodies and uses thereof
|
BR112020020826A2
(pt)
|
2018-04-12 |
2021-01-19 |
Bristol-Myers Squibb Company |
Terapia de combinação anticâncer com anticorpo antagonista de cd73 e anticorpo antagonista do eixo pd-1/pd-l1
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
US10973834B2
(en)
|
2018-04-16 |
2021-04-13 |
Arrys Therapeutics, Inc. |
EP4 inhibitors and use thereof
|
CN112074516A
(zh)
|
2018-04-25 |
2020-12-11 |
先天肿瘤免疫公司 |
Nlrp3调节剂
|
CA3096909A1
(en)
|
2018-04-26 |
2019-10-31 |
Agenus Inc. |
Heat shock protein-binding peptide compositions and methods of use thereof
|
US20230339891A1
(en)
|
2018-05-03 |
2023-10-26 |
Bristol-Myers Squibb Company |
Uracil derivatives as mer-axl inhibitors
|
WO2019211492A1
(en)
|
2018-05-04 |
2019-11-07 |
Tollys |
Tlr3 ligands that activate both epithelial and myeloid cells
|
SG11202010469QA
(en)
|
2018-05-23 |
2020-11-27 |
Adc Therapeutics Sa |
Molecular adjuvant
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
EP3810109A4
(en)
|
2018-05-31 |
2022-03-16 |
Peloton Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR INHIBITING CD73
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
CN112384531A
(zh)
|
2018-06-01 |
2021-02-19 |
诺华股份有限公司 |
针对bcma的结合分子及其用途
|
EP3802613A4
(en)
*
|
2018-06-05 |
2022-03-09 |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd. |
DIMERE AND ITS USE
|
KR20210035805A
(ko)
|
2018-06-15 |
2021-04-01 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
|
EP3807316A1
(en)
|
2018-06-18 |
2021-04-21 |
Innate Pharma |
Compositions and methods for treating cancer
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
TWI819011B
(zh)
|
2018-06-23 |
2023-10-21 |
美商建南德克公司 |
以pd-1 軸結合拮抗劑、鉑劑及拓撲異構酶ii 抑制劑治療肺癌之方法
|
CN112654621A
(zh)
|
2018-06-27 |
2021-04-13 |
百时美施贵宝公司 |
可作为t细胞活化剂的经取代萘啶酮化合物
|
JP7373512B2
(ja)
|
2018-06-27 |
2023-11-02 |
ブリストル-マイヤーズ スクイブ カンパニー |
T細胞アクティベーターとして有用なナフチリジノン化合物
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
JP7411627B2
(ja)
|
2018-07-09 |
2024-01-11 |
ファイヴ プライム セラピューティクス インク |
Ilt4と結合する抗体
|
CA3103385A1
(en)
|
2018-07-10 |
2020-01-16 |
Novartis Ag |
3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
TW202028235A
(zh)
|
2018-07-11 |
2020-08-01 |
美商戊瑞治療有限公司 |
於酸性ph結合至含免疫球蛋白v域之t細胞活化抑制子(vista)之抗體
|
WO2020014583A1
(en)
|
2018-07-13 |
2020-01-16 |
Bristol-Myers Squibb Company |
Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor
|
JP2021530502A
(ja)
|
2018-07-18 |
2021-11-11 |
ジェネンテック, インコーポレイテッド |
Pd−1軸結合アンタゴニスト、代謝拮抗剤、及びプラチナ製剤で肺がんを治療する方法
|
CA3106114A1
(en)
|
2018-07-20 |
2020-01-23 |
Surface Oncology, Inc. |
Anti-cd112r compositions and methods
|
WO2020023355A1
(en)
|
2018-07-23 |
2020-01-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US20210355113A1
(en)
|
2018-07-23 |
2021-11-18 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
JP2021532143A
(ja)
|
2018-07-26 |
2021-11-25 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
癌の処置のためのlag−3併用療法
|
WO2020021061A1
(en)
|
2018-07-26 |
2020-01-30 |
Pieris Pharmaceuticals Gmbh |
Humanized anti-pd-1 antibodies and uses thereof
|
EP3837015B1
(en)
|
2018-08-16 |
2024-02-14 |
Innate Tumor Immunity, Inc. |
Imidazo[4,5-c]quinoline derived nlrp3-modulators
|
MX2021001581A
(es)
|
2018-08-16 |
2021-04-19 |
Innate Tumor Immunity Inc |
Compuestos de 4-amino-1h-imidazo[4,5-c]quinolina sustituidos y metodos mejorados para su preparacion.
|
KR20210046023A
(ko)
|
2018-08-16 |
2021-04-27 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
이미다조[4,5-c]퀴놀린 유래 NLRP3-조정제
|
TW202026423A
(zh)
|
2018-08-24 |
2020-07-16 |
法商賽諾菲公司 |
用於實體瘤癌症的治療性rna
|
US20210246219A1
(en)
|
2018-08-27 |
2021-08-12 |
Pieris Pharmaceuticals Gmbh |
Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof
|
US10959986B2
(en)
|
2018-08-29 |
2021-03-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US11253525B2
(en)
|
2018-08-29 |
2022-02-22 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
WO2020044252A1
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Dosage regimes for anti-m-csf antibodies and uses thereof
|
TW202024023A
(zh)
|
2018-09-03 |
2020-07-01 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
WO2020049534A1
(en)
|
2018-09-07 |
2020-03-12 |
Novartis Ag |
Sting agonist and combination therapy thereof for the treatment of cancer
|
US20220089587A1
(en)
|
2018-09-07 |
2022-03-24 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
AU2019345151A1
(en)
|
2018-09-19 |
2021-04-29 |
Alpine Immune Sciences, Inc. |
Methods and uses of variant CD80 fusion proteins and related constructs
|
AU2019346466A1
(en)
|
2018-09-25 |
2021-05-20 |
Harpoon Therapeutics, Inc. |
DLL3 binding proteins and methods of use
|
KR20210072059A
(ko)
|
2018-10-09 |
2021-06-16 |
브리스톨-마이어스 스큅 컴퍼니 |
암을 치료하기 위한 항-MerTK 항체
|
JP2022504839A
(ja)
|
2018-10-10 |
2022-01-13 |
ティロス・セラピューティクス・インコーポレイテッド |
抗lap抗体変異体及びその使用
|
EP3867409A1
(en)
|
2018-10-16 |
2021-08-25 |
Novartis AG |
Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
|
MX2021003903A
(es)
|
2018-10-19 |
2021-06-04 |
Bristol Myers Squibb Co |
Terapia combinada para el melanoma.
|
JP2022505647A
(ja)
|
2018-10-23 |
2022-01-14 |
ブリストル-マイヤーズ スクイブ カンパニー |
腫瘍の処置方法
|
EP3873534A1
(en)
|
2018-10-29 |
2021-09-08 |
Mersana Therapeutics, Inc. |
Cysteine engineered antibody-drug conjugates with peptide-containing linkers
|
EP3873532A1
(en)
|
2018-10-31 |
2021-09-08 |
Novartis AG |
Dc-sign antibody drug conjugates
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
JP2022507606A
(ja)
|
2018-11-16 |
2022-01-18 |
ネオイミューンテック, インコーポレイテッド |
Il-7タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法
|
EP3880708A1
(en)
|
2018-11-16 |
2021-09-22 |
Bristol-Myers Squibb Company |
Anti-nkg2a antibodies and uses thereof
|
TW202038943A
(zh)
|
2018-11-19 |
2020-11-01 |
美商雅里俊公司 |
治療癌症之方法
|
CN113348177A
(zh)
|
2018-11-28 |
2021-09-03 |
百时美施贵宝公司 |
包含经修饰的重链恒定区的抗体
|
US11352350B2
(en)
|
2018-11-30 |
2022-06-07 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
MX2021006544A
(es)
|
2018-12-04 |
2021-07-07 |
Sumitomo Pharma Oncology Inc |
Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
|
EP3891508A1
(en)
|
2018-12-04 |
2021-10-13 |
Bristol-Myers Squibb Company |
Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring
|
EP3894401A2
(en)
|
2018-12-11 |
2021-10-20 |
Theravance Biopharma R&D IP, LLC |
Naphthyridine and quinoline derivatives useful as alk5 inhibitors
|
EP3666905A1
(en)
|
2018-12-11 |
2020-06-17 |
Sanofi |
E. coli positive for pks island as marker of positive response to anti-pd1 therapy in colorectal cancer
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
CA3123511A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
WO2020128613A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1beta binding antibodies
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
KR20210108422A
(ko)
|
2018-12-21 |
2021-09-02 |
노파르티스 아게 |
IL-1β 결합 항체의 용도
|
US20200369762A1
(en)
|
2018-12-21 |
2020-11-26 |
Novartis Ag |
Use of il-1beta binding antibodies
|
KR20210109564A
(ko)
|
2018-12-21 |
2021-09-06 |
옹쎄오 |
신규의 컨쥬게이티드 핵산 분자 및 이의 용도
|
EP3899951A1
(en)
|
2018-12-23 |
2021-10-27 |
F. Hoffmann-La Roche AG |
Tumor classification based on predicted tumor mutational burden
|
CN111423510B
(zh)
|
2019-01-10 |
2024-02-06 |
迈威(上海)生物科技股份有限公司 |
重组抗人pd-1抗体及其应用
|
CN113286786A
(zh)
|
2019-01-14 |
2021-08-20 |
先天肿瘤免疫公司 |
Nlrp3调节剂
|
JP2022517111A
(ja)
|
2019-01-14 |
2022-03-04 |
イネイト・テューマー・イミュニティ・インコーポレイテッド |
がんの治療に用いるためのヘテロ環nlrp3モジュレーター
|
EP3911416A1
(en)
|
2019-01-14 |
2021-11-24 |
Innate Tumor Immunity, Inc. |
Substituted quinazolines as nlrp3 modulators, for use in the treatment of cancer
|
WO2020150152A1
(en)
|
2019-01-14 |
2020-07-23 |
Genentech, Inc. |
Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine
|
CN113286787A
(zh)
|
2019-01-14 |
2021-08-20 |
先天肿瘤免疫公司 |
Nlrp3调节剂
|
AU2020209766A1
(en)
|
2019-01-17 |
2021-07-08 |
Georgia Tech Research Corporation |
Drug delivery systems containing oxidized cholesterols
|
TW202043274A
(zh)
|
2019-01-21 |
2020-12-01 |
法商賽諾菲公司 |
用於晚期實性瘤癌症之治療性rna及抗pd1抗體
|
EP3923940A1
(en)
|
2019-02-12 |
2021-12-22 |
Novartis AG |
Pharmaceutical combination comprising tno155 and a pd-1 inhibitor
|
JP2022520361A
(ja)
|
2019-02-12 |
2022-03-30 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
複素環式タンパク質キナーゼ阻害剤を含む製剤
|
WO2020168244A1
(en)
|
2019-02-15 |
2020-08-20 |
Incelldx, Inc. |
Assaying bladder-associated samples, identifying and treating bladder-associated neoplasia, and kits for use therein
|
US20220144807A1
(en)
|
2019-02-15 |
2022-05-12 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
AU2020222346B2
(en)
|
2019-02-15 |
2021-12-09 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
CN113993549A
(zh)
|
2019-03-15 |
2022-01-28 |
博尔特生物治疗药物有限公司 |
靶向her2的免疫缀合物
|
EA202192555A1
(ru)
|
2019-03-19 |
2021-11-25 |
Фундасио Привада Институт Д'Инвестигасио Онколохика Де Валь Эброн |
Комбинированная терапия для лечения рака
|
JP2022525149A
(ja)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
|
JP2022519923A
(ja)
|
2019-03-22 |
2022-03-25 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
Pkm2モジュレーターを含む組成物およびそれを使用する処置の方法
|
EP3946628A1
(en)
|
2019-03-28 |
2022-02-09 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
US20220041733A1
(en)
|
2019-03-28 |
2022-02-10 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
CA3135569A1
(en)
|
2019-04-02 |
2020-10-08 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
CN113939300A
(zh)
|
2019-04-05 |
2022-01-14 |
凯麦拉医疗公司 |
Stat降解剂和其用途
|
CN113906021A
(zh)
|
2019-04-15 |
2022-01-07 |
阿里根公司 |
手性吲哚化合物及其用途
|
EP3725370A1
(en)
|
2019-04-19 |
2020-10-21 |
ImmunoBrain Checkpoint, Inc. |
Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
|
CN114364703A
(zh)
|
2019-04-19 |
2022-04-15 |
豪夫迈·罗氏有限公司 |
抗mertk抗体及它们的使用方法
|
CN113784981A
(zh)
|
2019-04-23 |
2021-12-10 |
先天制药公司 |
Cd73阻断抗体
|
EP3962947A2
(en)
|
2019-05-03 |
2022-03-09 |
F. Hoffmann-La Roche AG |
Methods of treating cancer with an anti-pd-l1 antibody
|
EP3962493A2
(en)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
|
US20230242478A1
(en)
|
2019-05-13 |
2023-08-03 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
MX2021013815A
(es)
|
2019-05-13 |
2021-12-14 |
Regeneron Pharma |
Combinacion de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento contra el cancer.
|
US20230295087A1
(en)
|
2019-05-13 |
2023-09-21 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
US20220363760A1
(en)
|
2019-05-30 |
2022-11-17 |
Bristol-Myers Squibb Company |
Multi-tumor gene signature for suitability to immuno-oncology therapy
|
EP3977132A1
(en)
|
2019-05-30 |
2022-04-06 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
CN114127315A
(zh)
|
2019-05-30 |
2022-03-01 |
百时美施贵宝公司 |
鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
|
KR20220034739A
(ko)
|
2019-05-31 |
2022-03-18 |
이케나 온콜로지, 인코포레이티드 |
Tead 억제제 및 이의 용도
|
US11246906B2
(en)
|
2019-06-11 |
2022-02-15 |
Alkermes Pharma Ireland Limited |
Compositions and methods for subcutaneous administration of cancer immunotherapy
|
CN114206379A
(zh)
|
2019-06-18 |
2022-03-18 |
爱尔兰詹森科学公司 |
乙型肝炎病毒(hbv)疫苗和抗pd-1抗体的组合
|
KR20220041080A
(ko)
|
2019-06-18 |
2022-03-31 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
B형 간염 바이러스(hbv) 백신 및 항-pd-1 또는 항-pc-l1 항체의 조합
|
MX2022000164A
(es)
|
2019-07-03 |
2022-04-01 |
Sumitomo Pharma Oncology Inc |
Inhibidores de tirosina cinasa no receptora 1 (tnk1) y usos de los mismos.
|
US20220306630A1
(en)
|
2019-08-06 |
2022-09-29 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
GB201912107D0
(en)
|
2019-08-22 |
2019-10-09 |
Amazentis Sa |
Combination
|
AR119821A1
(es)
|
2019-08-28 |
2022-01-12 |
Bristol Myers Squibb Co |
Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
|
BR112022003740A2
(pt)
|
2019-08-30 |
2022-05-31 |
Agenus Inc |
Anticorpos anti-cd96 e métodos de uso dos mesmos
|
CN114761386A
(zh)
|
2019-09-17 |
2022-07-15 |
比亚尔R&D投资股份公司 |
作为酸性神经酰胺酶抑制剂的经取代n-杂环甲酰胺及其作为药物的用途
|
CN114787135A
(zh)
|
2019-09-17 |
2022-07-22 |
比亚尔R&D投资股份公司 |
经取代的咪唑甲酰胺及其在治疗医学病症中的用途
|
WO2021055630A1
(en)
|
2019-09-17 |
2021-03-25 |
Bial- Biotech Investments, Inc. |
Substituted, saturated and unsaturated n-heterocyclic carboxamides and related compounds for their use in the treatment of medical disorders
|
EP4031578A1
(en)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
TW202124448A
(zh)
|
2019-09-19 |
2021-07-01 |
美商必治妥美雅史谷比公司 |
於酸性pH結合VISTA之抗體
|
CN114450028A
(zh)
|
2019-09-22 |
2022-05-06 |
百时美施贵宝公司 |
Lag-3拮抗剂治疗的定量空间剖析
|
JP2022549337A
(ja)
|
2019-09-25 |
2022-11-24 |
ブリストル-マイヤーズ スクイブ カンパニー |
がん療法のための複合バイオマーカー
|
CN114728046A
(zh)
|
2019-09-25 |
2022-07-08 |
思进公司 |
联合抗cd30 adc、抗pd-1和化疗以治疗血液癌症
|
CN114514037A
(zh)
|
2019-09-30 |
2022-05-17 |
阿斯利康(瑞典)有限公司 |
用于癌症的组合治疗
|
CA3151322A1
(en)
|
2019-10-01 |
2021-04-08 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
BR112022007179A2
(pt)
|
2019-10-21 |
2022-08-23 |
Novartis Ag |
Inibidores de tim-3 e usos dos mesmos
|
TW202128166A
(zh)
|
2019-10-21 |
2021-08-01 |
瑞士商諾華公司 |
組合療法
|
CA3155345A1
(en)
|
2019-11-04 |
2021-05-14 |
Spencer LIANG |
Siglec-9 ecd fusion molecules and methods of use thereof
|
WO2021090146A1
(en)
|
2019-11-04 |
2021-05-14 |
Astrazeneca Ab |
Combination therapy for treating cancer
|
KR20220092578A
(ko)
|
2019-11-05 |
2022-07-01 |
브리스톨-마이어스 스큅 컴퍼니 |
M-단백질 검정 및 이의 용도
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
MX2022005474A
(es)
|
2019-11-08 |
2022-06-02 |
Bristol Myers Squibb Co |
Tratamiento de melanoma con antagonistas del gen 3 de activacion de linfocitos (lag-3).
|
MX2022005775A
(es)
|
2019-11-13 |
2022-06-09 |
Genentech Inc |
Compuestos terapeuticos y metodos de uso.
|
US20220395553A1
(en)
|
2019-11-14 |
2022-12-15 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
AR120481A1
(es)
|
2019-11-19 |
2022-02-16 |
Bristol Myers Squibb Co |
Compuestos útiles como inhibidores de la proteína helios
|
US20230000864A1
(en)
|
2019-11-22 |
2023-01-05 |
Sumitomo Pharma Oncology, Inc. |
Solid dose pharmaceutical composition
|
KR20220104208A
(ko)
|
2019-11-22 |
2022-07-26 |
세라밴스 바이오파마 알앤디 아이피, 엘엘씨 |
Alk5 억제제로서 치환된 1,5-나프티리딘 또는 퀴놀린
|
US11591339B2
(en)
|
2019-11-26 |
2023-02-28 |
Ikena Oncology, Inc. |
Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[ 1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine maleate as aryl hydrocarbon receptor (AHR) inhibitors
|
KR20220104794A
(ko)
|
2019-11-26 |
2022-07-26 |
브리스톨-마이어스 스큅 컴퍼니 |
(r)-n-(4-클로로페닐)-2-((1s,4s)-4-(6-플루오로퀴놀린-4-일)시클로헥실)프로판아미드의 염/공결정
|
GB201917254D0
(en)
|
2019-11-27 |
2020-01-08 |
Adc Therapeutics Sa |
Combination therapy
|
US11897950B2
(en)
|
2019-12-06 |
2024-02-13 |
Augusta University Research Institute, Inc. |
Osteopontin monoclonal antibodies
|
CA3164124A1
(en)
|
2019-12-09 |
2021-06-17 |
Seagen Inc. |
Combination therapy with liv1-adc and pd-1 antagonist
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
WO2021127217A1
(en)
|
2019-12-17 |
2021-06-24 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
IL293917A
(en)
|
2019-12-17 |
2022-08-01 |
Kymera Therapeutics Inc |
Iraq joints and their uses
|
KR20220118481A
(ko)
|
2019-12-19 |
2022-08-25 |
브리스톨-마이어스 스큅 컴퍼니 |
Dgk 억제제 및 체크포인트 길항제의 조합물
|
CN115052662A
(zh)
|
2019-12-20 |
2022-09-13 |
诺华股份有限公司 |
抗TGFβ抗体和检查点抑制剂用于治疗增殖性疾病的用途
|
AR120823A1
(es)
|
2019-12-23 |
2022-03-23 |
Bristol Myers Squibb Co |
Compuestos bicíclicos sustituidos útiles como activadores de células t
|
WO2021133752A1
(en)
|
2019-12-23 |
2021-07-01 |
Bristol-Myers Squibb Company |
Substituted heteroaryl compounds useful as t cell activators
|
JP2023508375A
(ja)
|
2019-12-23 |
2023-03-02 |
ブリストル-マイヤーズ スクイブ カンパニー |
T細胞アクティベーターとして有用な置換ピペラジン誘導体
|
KR20220151160A
(ko)
|
2019-12-23 |
2022-11-14 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Smarca 분해제 및 이의 용도
|
IL294148A
(en)
|
2019-12-23 |
2022-08-01 |
Bristol Myers Squibb Co |
Substituted quinazolinyl compounds are useful as t-cell activators
|
JP2023508055A
(ja)
|
2019-12-23 |
2023-02-28 |
ブリストル-マイヤーズ スクイブ カンパニー |
T細胞アクティベーターとして有用な置換キノリノニルピペラジン化合物
|
WO2021141907A1
(en)
|
2020-01-06 |
2021-07-15 |
Hifibio (Hong Kong) Limited |
Anti-tnfr2 antibody and uses thereof
|
JP2023510429A
(ja)
|
2020-01-07 |
2023-03-13 |
ハイファイバイオ (エイチケー) リミテッド |
抗ガレクチン-9抗体およびその使用
|
KR20220127848A
(ko)
|
2020-01-10 |
2022-09-20 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
Nlrp3 조정제
|
TW202140473A
(zh)
|
2020-01-15 |
2021-11-01 |
美商纜圖藥品公司 |
Map4k1抑制劑
|
US20230058489A1
(en)
|
2020-01-17 |
2023-02-23 |
Novartis Ag |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
US20230090446A1
(en)
|
2020-01-28 |
2023-03-23 |
Universite De Strasbourg |
Antisense oligonucleotide targeting linc00518 for treating melanoma
|
KR20220132598A
(ko)
|
2020-01-28 |
2022-09-30 |
제넨테크, 인크. |
암 치료를 위한 IL15/IL15R 알파 이종이량체 Fc-융합 단백질
|
BR112022014962A2
(pt)
|
2020-01-30 |
2022-09-20 |
Ona Therapeutics S L |
Terapia de combinação para tratamento de câncer e metástase de câncer
|
CN115397459A
(zh)
|
2020-01-31 |
2022-11-25 |
基因泰克公司 |
用pd-1轴结合拮抗剂和rna疫苗诱导新表位特异性t细胞的方法
|
KR20220139915A
(ko)
|
2020-02-06 |
2022-10-17 |
브리스톨-마이어스 스큅 컴퍼니 |
Il-10 및 그의 용도
|
US20230220074A1
(en)
|
2020-02-18 |
2023-07-13 |
Alector Llc |
Pilra antibodies and methods of use thereof
|
AU2021225491A1
(en)
|
2020-02-28 |
2022-10-20 |
Novartis Ag |
A triple pharmaceutical combination comprising dabrafenib, an Erk inhibitor and a RAF inhibitor
|
US11753403B2
(en)
|
2020-03-03 |
2023-09-12 |
PIC Therapeutics, Inc. |
EIF4E inhibitors and uses thereof
|
WO2022074464A2
(en)
|
2020-03-05 |
2022-04-14 |
Neotx Therapeutics Ltd. |
Methods and compositions for treating cancer with immune cells
|
CN115484958A
(zh)
|
2020-03-06 |
2022-12-16 |
赛尔基因昆蒂赛尔研究公司 |
用于治疗sclc或sqnsclc的lsd-1抑制剂和纳武单抗的组合
|
WO2021176424A1
(en)
|
2020-03-06 |
2021-09-10 |
Ona Therapeutics, S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
JP2023516459A
(ja)
|
2020-03-09 |
2023-04-19 |
ブリストル-マイヤーズ スクイブ カンパニー |
増強されたアゴニスト活性を有するcd40に対する抗体
|
BR112022018678A2
(pt)
|
2020-03-19 |
2022-11-01 |
Kymera Therapeutics Inc |
Degradadores de mdm2 e usos dos mesmos
|
AU2021240068A1
(en)
|
2020-03-19 |
2022-09-08 |
Arcus Biosciences, Inc. |
Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
|
TW202140441A
(zh)
|
2020-03-23 |
2021-11-01 |
美商必治妥美雅史谷比公司 |
經取代之側氧基異吲哚啉化合物
|
WO2021194942A1
(en)
|
2020-03-23 |
2021-09-30 |
Bristol-Myers Squibb Company |
Anti-ccr8 antibodies for treating cancer
|
US11673879B2
(en)
|
2020-03-31 |
2023-06-13 |
Theravance Biopharma R&D Ip, Llc |
Substituted pyrimidines and methods of use
|
WO2021207449A1
(en)
|
2020-04-09 |
2021-10-14 |
Merck Sharp & Dohme Corp. |
Affinity matured anti-lap antibodies and uses thereof
|
MX2022013031A
(es)
|
2020-04-21 |
2023-01-04 |
Novartis Ag |
Regimen de dosificacion para el tratamiento de una enfermedad modulada por csf-1r.
|
SE2050559A1
(en)
*
|
2020-05-13 |
2021-11-14 |
Khs Biomedinvent Ab |
PD-1 as a predictive marker for therapy in cancer
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
EP4157875A1
(en)
|
2020-06-02 |
2023-04-05 |
Arcus Biosciences, Inc. |
Antibodies to tigit
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
WO2021253041A1
(en)
|
2020-06-10 |
2021-12-16 |
Theravance Biopharma R&D Ip, Llc |
Naphthyridine derivatives useful as alk5 inhibitors
|
KR20230024967A
(ko)
|
2020-06-11 |
2023-02-21 |
노파르티스 아게 |
Zbtb32 억제제 및 이의 용도
|
AR122644A1
(es)
|
2020-06-19 |
2022-09-28 |
Onxeo |
Nuevas moléculas de ácido nucleico conjugado y sus usos
|
WO2021258010A1
(en)
|
2020-06-19 |
2021-12-23 |
Gossamer Bio Services, Inc. |
Oxime compounds useful as t cell activators
|
EP4168007A1
(en)
|
2020-06-23 |
2023-04-26 |
Novartis AG |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
US20230355804A1
(en)
|
2020-06-29 |
2023-11-09 |
Flagship Pioneering Innovations V, Inc. |
Viruses engineered to promote thanotransmission and their use in treating cancer
|
WO2022003568A1
(en)
|
2020-06-30 |
2022-01-06 |
Dcprime B.V. |
Use of leukemia-derived cells in ovarian cancer vaccines
|
WO2022008519A1
(en)
|
2020-07-07 |
2022-01-13 |
BioNTech SE |
Therapeutic rna for hpv-positive cancer
|
WO2022009157A1
(en)
|
2020-07-10 |
2022-01-13 |
Novartis Ag |
Lhc165 and spartalizumab combinations for treating solid tumors
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
KR20230044480A
(ko)
|
2020-07-30 |
2023-04-04 |
카이메라 쎄라퓨틱스 인코포레이티드 |
돌연변이 림프종의 치료 방법
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
MX2023001707A
(es)
|
2020-08-10 |
2023-05-04 |
Shanghai Xunbaihui Biotechnology Co Ltd |
Composiciones y métodos para el tratamiento de enfermedades autoinmunes y cánceres por direccionamiento al miembro 8 de la superfamilia de inmunoglobulinas.
|
KR20230050389A
(ko)
|
2020-08-13 |
2023-04-14 |
브리스톨-마이어스 스큅 컴퍼니 |
Il-2를 관심 표적 세포로 재지시하는 방법
|
WO2022038158A1
(en)
|
2020-08-17 |
2022-02-24 |
Bicycletx Limited |
Bicycle conjugates specific for nectin-4 and uses thereof
|
WO2022046833A1
(en)
|
2020-08-26 |
2022-03-03 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer by administering a pd-1 inhibitor
|
BR112023003427A2
(pt)
|
2020-08-28 |
2023-03-21 |
Bristol Myers Squibb Co |
Terapia com antagonista de lag-3 para carcinoma hepatocelular
|
WO2022043558A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
JP2023538955A
(ja)
|
2020-08-31 |
2023-09-12 |
ブリストル-マイヤーズ スクイブ カンパニー |
細胞局在シグネチャーおよび免疫療法
|
JP2023544410A
(ja)
|
2020-10-05 |
2023-10-23 |
ブリストル-マイヤーズ スクイブ カンパニー |
タンパク質を濃縮するための方法
|
WO2022076596A1
(en)
|
2020-10-06 |
2022-04-14 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting stat6
|
WO2022086957A1
(en)
|
2020-10-20 |
2022-04-28 |
Genentech, Inc. |
Peg-conjugated anti-mertk antibodies and methods of use
|
EP4232019A1
(en)
|
2020-10-23 |
2023-08-30 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for lung cancer
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
AU2021369590A1
(en)
|
2020-10-28 |
2023-06-22 |
Ikena Oncology, Inc. |
Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
|
CA3196191A1
(en)
|
2020-11-04 |
2022-05-12 |
Chi-Chung Li |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
CA3196076A1
(en)
|
2020-11-04 |
2022-05-12 |
Chi-Chung Li |
Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
|
KR20230095119A
(ko)
|
2020-11-04 |
2023-06-28 |
제넨테크, 인크. |
항-cd20/항-cd3 이중특이적 항체를 사용한 치료를 위한 투약
|
AU2021373366A1
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
IL301268A
(en)
|
2020-11-13 |
2023-05-01 |
Genentech Inc |
Methods and compositions containing a KRASG12C inhibitor and a PD-L1 binding antagonist for the treatment of lung cancer
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
CA3202523A1
(en)
|
2020-12-02 |
2022-06-09 |
Genentech, Inc. |
Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy
|
WO2022120354A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
CA3201219A1
(en)
|
2020-12-04 |
2022-06-09 |
Mir Ali |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Alk﹘5抑制劑和彼之用途
|
CN116964050A
(zh)
|
2020-12-16 |
2023-10-27 |
戈萨默生物服务公司 |
可用作t细胞激活剂的化合物
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性rna
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
CA3201348A1
(en)
|
2020-12-28 |
2022-07-07 |
Masano HUANG |
Antibody compositions and methods of use thereof
|
CA3196999A1
(en)
|
2020-12-28 |
2022-07-07 |
Masano HUANG |
Methods of treating tumors
|
US20240050564A1
(en)
|
2021-01-08 |
2024-02-15 |
Bristol-Myers Squibb Company |
Combination therapy using an anti-fucosyl-gm1 antibody
|
WO2022148979A1
(en)
|
2021-01-11 |
2022-07-14 |
Bicycletx Limited |
Methods for treating cancer
|
EP4281102A1
(en)
|
2021-01-22 |
2023-11-29 |
Mendus B.V. |
Methods of tumor vaccination
|
JP2024506557A
(ja)
|
2021-01-29 |
2024-02-14 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
修飾された腫瘍浸潤リンパ球を作製する方法及び養子細胞療法におけるそれらの使用
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗cd73及び抗entpd2抗体のための投与方式並びにその使用
|
KR20230152692A
(ko)
|
2021-02-02 |
2023-11-03 |
리미널 바이오사이언시스 리미티드 |
Gpr84 길항제 및 이의 용도
|
BR112023015590A2
(pt)
|
2021-02-02 |
2023-10-17 |
Liminal Biosciences Ltd |
Antagonistas de gpr84 e usos dos mesmos
|
WO2022169921A1
(en)
|
2021-02-04 |
2022-08-11 |
Bristol-Myers Squibb Company |
Benzofuran compounds as sting agonists
|
AU2022221124A1
(en)
|
2021-02-12 |
2023-08-03 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives for the treatment of cancer
|
CA3207380A1
(en)
|
2021-02-15 |
2022-08-18 |
Haojing RONG |
Irak4 degraders and uses thereof
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
JP2024509192A
(ja)
|
2021-03-05 |
2024-02-29 |
ニンバス サターン, インコーポレイテッド |
Hpk1アンタゴニスト及びその使用
|
JP2024510176A
(ja)
|
2021-03-08 |
2024-03-06 |
ブループリント メディシンズ コーポレイション |
Map4k1阻害剤
|
AU2022235341A1
(en)
|
2021-03-12 |
2023-09-21 |
Mendus B.V. |
Methods of vaccination and use of cd47 blockade
|
WO2022197641A1
(en)
|
2021-03-15 |
2022-09-22 |
Rapt Therapeutics, Inc. |
1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
|
EP4308935A1
(en)
|
2021-03-18 |
2024-01-24 |
Novartis AG |
Biomarkers for cancer and methods of use thereof
|
WO2022204672A1
(en)
|
2021-03-23 |
2022-09-29 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor
|
TW202304506A
(zh)
|
2021-03-25 |
2023-02-01 |
日商安斯泰來製藥公司 |
涉及抗claudin 18.2抗體的組合治療以治療癌症
|
IL307262A
(en)
|
2021-03-29 |
2023-11-01 |
Juno Therapeutics Inc |
METHODS FOR DOSAGE AND THERAPY IN COMBINATION OF CHECKPOINT INHIBITOR AND CAR T CELL THERAPY
|
WO2022212784A1
(en)
|
2021-03-31 |
2022-10-06 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
WO2022212876A1
(en)
|
2021-04-02 |
2022-10-06 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
KR20230167067A
(ko)
|
2021-04-05 |
2023-12-07 |
브리스톨-마이어스 스큅 컴퍼니 |
암의 치료를 위한 피리디닐 치환된 옥소이소인돌린 화합물
|
AR125298A1
(es)
|
2021-04-06 |
2023-07-05 |
Bristol Myers Squibb Co |
Compuestos de oxoisoindolina sustituidos con piridinilo
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
CA3213079A1
(en)
|
2021-04-13 |
2022-10-20 |
Kristin Lynne ANDREWS |
Amino-substituted heterocycles for treating cancers with egfr mutations
|
JP2024514879A
(ja)
|
2021-04-16 |
2024-04-03 |
イケナ オンコロジー, インコーポレイテッド |
Mek阻害剤及びその使用
|
KR20240005691A
(ko)
|
2021-04-30 |
2024-01-12 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이적 항체 및 항-cd79b 항체 약물 접합체를 이용한 병용 치료를 위한 투약
|
JP2024516230A
(ja)
|
2021-04-30 |
2024-04-12 |
ジェネンテック, インコーポレイテッド |
がんのための治療及び診断方法並びに組成物
|
CA3219336A1
(en)
|
2021-05-18 |
2022-11-24 |
Kymab Limited |
Uses of anti-icos antibodies
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
CN117337288A
(zh)
|
2021-05-21 |
2024-01-02 |
艾库斯生物科学有限公司 |
Axl抑制剂化合物
|
TW202313602A
(zh)
|
2021-05-21 |
2023-04-01 |
美商阿克思生物科學有限公司 |
Axl化合物
|
WO2022251359A1
(en)
|
2021-05-26 |
2022-12-01 |
Theravance Biopharma R&D Ip, Llc |
Bicyclic inhibitors of alk5 and methods of use
|
GB202107994D0
(en)
|
2021-06-04 |
2021-07-21 |
Kymab Ltd |
Treatment of cancer
|
US20230036928A1
(en)
|
2021-06-18 |
2023-02-02 |
Genzyme Corporation |
Anti-tgf-beta antibody formulations and their use
|
CA3224374A1
(en)
|
2021-06-29 |
2023-01-05 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
TW202309078A
(zh)
|
2021-07-02 |
2023-03-01 |
美商建南德克公司 |
治療癌症之方法及組成物
|
CA3225254A1
(en)
|
2021-07-13 |
2023-01-19 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
TW202321237A
(zh)
|
2021-07-14 |
2023-06-01 |
美商纜圖藥品公司 |
Map4k1抑制劑
|
TW202321238A
(zh)
|
2021-07-15 |
2023-06-01 |
美商纜圖藥品公司 |
Map4k1抑制劑
|
CA3224180A1
(en)
|
2021-07-28 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating cancer
|
WO2023010094A2
(en)
|
2021-07-28 |
2023-02-02 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
CA3226281A1
(en)
|
2021-07-30 |
2023-02-02 |
ONA Therapeutics S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
WO2023012147A1
(en)
|
2021-08-03 |
2023-02-09 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies and methods of use
|
WO2023015198A1
(en)
|
2021-08-04 |
2023-02-09 |
Genentech, Inc. |
Il15/il15r alpha heterodimeric fc-fusion proteins for the expansion of nk cells in the treatment of solid tumours
|
WO2023020315A1
(zh)
*
|
2021-08-19 |
2023-02-23 |
南京吉盛澳玛生物医药有限公司 |
靶向pd-l1/pd-1的抗体及其应用
|
CA3229448A1
(en)
|
2021-08-23 |
2023-03-02 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
WO2023028238A1
(en)
|
2021-08-25 |
2023-03-02 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
US20230150997A1
(en)
|
2021-08-25 |
2023-05-18 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
TW202321308A
(zh)
|
2021-09-30 |
2023-06-01 |
美商建南德克公司 |
使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
CA3234647A1
(en)
|
2021-10-06 |
2023-04-13 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 in combination therapy
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
WO2023077034A1
(en)
|
2021-10-28 |
2023-05-04 |
Lyell Immunopharma, Inc. |
Methods for culturing immune cells
|
IL309227A
(en)
|
2021-10-29 |
2024-02-01 |
Bristol Myers Squibb Co |
LAG-3 antagonist therapy for hematological cancer
|
WO2023077046A1
(en)
|
2021-10-29 |
2023-05-04 |
Arcus Biosciences, Inc. |
Inhibitors of hif-2alpha and methods of use thereof
|
WO2023080900A1
(en)
|
2021-11-05 |
2023-05-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating kidney cancer
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
WO2023084445A1
(en)
|
2021-11-12 |
2023-05-19 |
Novartis Ag |
Combination therapy for treating lung cancer
|
TW202332429A
(zh)
|
2021-11-24 |
2023-08-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
US20230203062A1
(en)
|
2021-11-24 |
2023-06-29 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
WO2023111203A1
(en)
|
2021-12-16 |
2023-06-22 |
Onxeo |
New conjugated nucleic acid molecules and their uses
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2023122777A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
WO2023122772A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
WO2023122778A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Pyridazinone derivatives useful as t cell activators
|
WO2023137161A1
(en)
|
2022-01-14 |
2023-07-20 |
Amgen Inc. |
Triple blockade of tigit, cd112r, and pd-l1
|
WO2023147371A1
(en)
|
2022-01-26 |
2023-08-03 |
Bristol-Myers Squibb Company |
Combination therapy for hepatocellular carcinoma
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
WO2023150186A1
(en)
|
2022-02-01 |
2023-08-10 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
WO2023159102A1
(en)
|
2022-02-17 |
2023-08-24 |
Regeneron Pharmaceuticals, Inc. |
Combinations of checkpoint inhibitors and oncolytic virus for treating cancer
|
WO2023161453A1
(en)
|
2022-02-24 |
2023-08-31 |
Amazentis Sa |
Uses of urolithins
|
WO2023164638A1
(en)
|
2022-02-25 |
2023-08-31 |
Bristol-Myers Squibb Company |
Combination therapy for colorectal carcinoma
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
WO2023170606A1
(en)
|
2022-03-08 |
2023-09-14 |
Alentis Therapeutics Ag |
Use of anti-claudin-1 antibodies to increase t cell availability
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023174210A1
(en)
|
2022-03-14 |
2023-09-21 |
Laekna Limited |
Combination treatment for cancer
|
WO2023178329A1
(en)
|
2022-03-18 |
2023-09-21 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023192478A1
(en)
|
2022-04-01 |
2023-10-05 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
WO2023196987A1
(en)
|
2022-04-07 |
2023-10-12 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
US20230326022A1
(en)
|
2022-04-08 |
2023-10-12 |
Bristol-Myers Squibb Company |
Machine Learning Identification, Classification, and Quantification of Tertiary Lymphoid Structures
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
WO2023215719A1
(en)
|
2022-05-02 |
2023-11-09 |
Arcus Biosciences, Inc. |
Anti-tigit antibodies and uses of the same
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023220703A1
(en)
|
2022-05-12 |
2023-11-16 |
Genentech, Inc. |
Methods and compositions comprising a shp2 inhibitor and a pd-l1 binding antagonist
|
WO2023218046A1
(en)
|
2022-05-12 |
2023-11-16 |
Genmab A/S |
Binding agents capable of binding to cd27 in combination therapy
|
WO2023222854A1
(en)
|
2022-05-18 |
2023-11-23 |
Kymab Limited |
Uses of anti-icos antibodies
|
US11878958B2
(en)
|
2022-05-25 |
2024-01-23 |
Ikena Oncology, Inc. |
MEK inhibitors and uses thereof
|
WO2023235847A1
(en)
|
2022-06-02 |
2023-12-07 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023240156A1
(en)
|
2022-06-08 |
2023-12-14 |
Tidal Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
US20240124490A1
(en)
|
2022-07-15 |
2024-04-18 |
Arcus Biosciences, Inc. |
Inhibitors of hpk1 and methods of use thereof
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020034A1
(en)
|
2022-07-20 |
2024-01-25 |
Arcus Biosciences, Inc. |
Cbl-b inhibitors and methods of use thereof
|
EP4310197A1
(en)
|
2022-07-21 |
2024-01-24 |
Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda |
Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy
|
WO2024023740A1
(en)
|
2022-07-27 |
2024-02-01 |
Astrazeneca Ab |
Combinations of recombinant virus expressing interleukin-12 with pd-1/pd-l1 inhibitors
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
WO2024028363A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
WO2024036100A1
(en)
|
2022-08-08 |
2024-02-15 |
Bristol-Myers Squibb Company |
Substituted tetrazolyl compounds useful as t cell activators
|
WO2024036101A1
(en)
|
2022-08-09 |
2024-02-15 |
Bristol-Myers Squibb Company |
Tertiary amine substituted bicyclic compounds useful as t cell activators
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024040175A1
(en)
|
2022-08-18 |
2024-02-22 |
Pulmatrix Operating Company, Inc. |
Methods for treating cancer using inhaled angiogenesis inhibitor
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024059142A1
(en)
|
2022-09-14 |
2024-03-21 |
Arcus Biosciences, Inc. |
Dispersions of etrumadenant
|
WO2024069009A1
(en)
|
2022-09-30 |
2024-04-04 |
Alentis Therapeutics Ag |
Treatment of drug-resistant hepatocellular carcinoma
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
WO2024077095A1
(en)
|
2022-10-05 |
2024-04-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating bladder cancer
|
WO2024077166A1
(en)
|
2022-10-05 |
2024-04-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating lung cancer
|